Foghorn Therapeutics Inc.
FHTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001822462
No open-market purchases or sales by Foghorn Therapeutics Inc. insiders were filed in the last 90 days; 102 institutions reported holding it in 13F filings for Q2 2026, worth $219.2M in total; no superinvestor holds it.
Holders of 5% or more of FHTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Foghorn Therapeutics Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Flagship Ventures Fund V, L.P. | 13D/A | 27.20%20.8M shares | – | May 24, 20242 filings | Jan 13, 2026 | SEC |
| FMR LLC | 13G/A | 11.60%6.79M shares | +1.40 ppfrom 10.20% | Feb 8, 20217 filings | May 6, 2026 | SEC |
| Biotechnology Value Fund L P | 13G/A | 9.99%5.87M shares | – | May 30, 20242 filings | May 15, 2026 | SEC |
| Flynn James E | 13G/A | 8.64%5.14M shares | – | Sep 20, 20242 filings | May 14, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
17 Schedule 13D and 13G filings on Foghorn Therapeutics Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 15, 20264:09 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%5.87M shares | – | Mar 31, 2026 | SEC |
| May 14, 20266:20 PM ET | Flynn James Eand 3 others | 13G/A | 8.64%5.14M shares | – | Mar 31, 2026 | SEC |
| May 6, 202611:18 AM ET | FMR LLCand 1 other | 13G/A | 11.60%6.79M shares | +1.40 ppfrom 10.20% | Mar 31, 2026 | SEC |
| Jan 13, 20265:09 PM ET | Flagship Ventures Fund V, L.P.and 9 others | 13D/A | 27.20%20.8M shares | – | Jan 9, 2026 | SEC |
| Feb 12, 20259:28 AM ET | FMR LLCand 1 other | 13G/A | 10.20%5.69M shares | – | Dec 31, 2024 | SEC |
| Oct 8, 2024 | Klarman Family Foundation | 13G/AOld format | – | – | – | SEC |
| Sep 20, 2024 | Flynn James E | 13GOld format | – | New | – | SEC |
| Jun 10, 2024 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| May 30, 2024 | Biotechnology Value Fund L P | 13GOld format | – | New | – | SEC |
| May 24, 2024 | Flagship Ventures Fund V, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 9, 2024 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2022 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Dec 13, 20218:16 AM ET | Eli Lilly & Co | 13GOld format | – | New | – | SEC |
| Apr 19, 2021 | Kadoch Cigall | 13GOld format | – | New | – | SEC |
| Feb 8, 2021 | FMR LLC | 13GOld format | – | New | – | SEC |
| Feb 4, 2021 | Klarman Family Foundation | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Foghorn Therapeutics Inc. shares.
No Form 144 notices for Foghorn Therapeutics Inc. are on file.